# Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

> **NCT00142129** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 27 (—)

## Conditions studied

- Waldenstrom's Macroglobulinemia
- Lymphoplasmacytic Lymphoma

## Interventions

- **DRUG:** Bortezomib (Velcade)

## Key facts

- **NCT ID:** NCT00142129
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 27 (—)
- **Last updated:** 2011-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142129, "Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00142129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*